PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
3.54%
G&A growth less than half of TRAW's 68.97%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
-10.44%
Operating expenses reduction while TRAW shows 17.77% growth. Joel Greenblatt would examine advantage.
-10.44%
Total costs reduction while TRAW shows 17.77% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
721.68%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
11.90%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
10.28%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS change of 12.12% while TRAW is flat. Bruce Berkowitz would examine quality.
10.49%
Diluted EPS change of 10.49% while TRAW is flat. Bruce Berkowitz would examine quality.
2.21%
Share count change of 2.21% while TRAW is stable. Bruce Berkowitz would verify approach.
No Data
No Data available this quarter, please select a different quarter.